In a report released today, Patrick Trucchio from H.C. Wainwright maintained a Buy rating on Invivyd (IVVD – Research Report), with a price ...

H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on Nuvectis Pharma (NVCT) to $11 from $21 and keeps a Buy rating on ...

IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell ...

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Michael Klichinsky, PharmD, PhD, Co-founder and Chief ...

In consideration for the immediate exercise of the existing warrants for cash at an exercise price of $2.27 per share, the ...

Thursday, H.C. Wainwright reaffirmed a Buy rating on Precision BioSciences Inc . (NASDAQ:DTIL) with a steady price target of $60.00, significantly above the current trading price of $5.65. The ...

Thursday, H.C. Wainwright reaffirmed a Buy rating on Precision BioSciences Inc . (NASDAQ:DTIL) with a steady price target of $60.00, significantly above the current trading price of $5.65.

will participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25 at 10:30 am ET. An audio webcast of the event will be available on the Company's ...

Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), a leader in AI-driven drug discovery and ...